MedTrace Logo

Efficacy of CL22205 on Bone Mineral Density and Menopausal Symptoms

NCT06899243 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-03-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of CL22205 on bone mineral density and menopausal symptoms in women.

Conditions

  • Menopausal Symptoms

Interventions

DIETARY_SUPPLEMENT

CL22205

200 mg, Route : Oral, One capsule a day after breakfast for 360 days

OTHER

Placebo

Route : Oral, One capsule a day after breakfast for 360 days

Sponsors & Collaborators

  • Eetho Brands, Inc

    lead INDUSTRY

Principal Investigators

  • Dr Arti Dibya, MBBS, MS DGO · Vastalya Hospital and multispecialty Centre

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-25
Primary Completion
2026-05-10
Completion
2026-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06899243 on ClinicalTrials.gov